<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125975">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01774474</url>
  </required_header>
  <id_info>
    <org_study_id>NL42463.068.12</org_study_id>
    <nct_id>NCT01774474</nct_id>
  </id_info>
  <brief_title>PRevention of Macular EDema After Cataract Surgery</brief_title>
  <acronym>PREMED</acronym>
  <official_title>PRevention of Macular EDema After Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society of Cataract and Refractive Surgeons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystoid macular edema (CME) is a swelling of the central and most important part of the
      retina. It is a common cause of vision loss after cataract surgery. In the last few years,
      several new treatments have been tried to address the problem of CME after cataract surgery
      in diabetic and non-diabetic patients. However, no randomised controlled clinical trial
      (RCT) has compared all the currently existing preventive interventions and no study has been
      conducted to investigate whether combining different preventive strategies has an additional
      effect. Therefore, the investigators will perform a large RCT with the aim to provide more
      definite evidence-based recommendations for clinical guidelines to prevent the occurrence of
      CME after cataract surgery in patients with and without diabetes mellitus (DM). The outcomes
      of this RCT will be of benefit to all cataract surgeons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the effect of different preventive strategies on
      the occurrence of macular edema after cataract surgery in non-diabetic and diabetic
      patients. The design of the study is a multicentre randomised controlled clinical trial with
      a duration of 33 months. The study population will consist of 1050 non-diabetic patients and
      300 patients with diabetes mellitus (DM) who require cataract surgery in at least one eye.
      All patients will receive a phacoemulsification for cataract and placement of a posterior
      chamber intraocular lens (IOL).

      In the non-diabetic population, the patients will receive either bromfenac 0.09% eye drops
      twice daily starting two days before surgery and continuing 2 weeks postoperative,
      dexamethasone 0.1% eye drops four times daily starting two days before surgery and
      continuing four times daily during the first postoperative week and one drop less per day
      every following week or a combination of both drugs.

      In the diabetic population patients will receive either:

        -  Topical bromfenac 0.09% and dexamethasone 0.1% in the aforementioned dose;

        -  Topical bromfenac 0.09% and dexamethasone 0.1% in the aforementioned dose and a
           subconjunctival injection of 40 mg triamcinolone acetonide (Triesence/Vistrec);

        -  Topical bromfenac 0.09% and dexamethasone 0.1% in the aforementioned dose and an
           intravitreal injection of 1.25 mg bevacizumab (Avastin);

        -  Topical bromfenac 0.09% and dexamethasone 0.1% in the aforementioned dose, a
           subconjunctival injection of 40 mg triamcinolone acetonide and an intravitreal
           injection of 1.25 mg bevacizumab.

      The primary endpoint is the change in central subfield mean macular thickness in the 1 mm
      area (central subfield macular thickness, CSMT) as compared to baseline within the first 6
      weeks postoperative.

      The secondary endpoint is the occurrence of postoperative clinically significant macular
      edema (CSME) within 12 weeks postoperatively. Other study endpoints are mean CDVA in logMAR
      at 6 weeks and 12 weeks postoperatively; OCT measured average retinal thickness in the
      central inner circle (3mm), the outer circle (6mm), and the macular volume at 6 weeks and 12
      weeks postoperatively; intraocular pressure at 6 weeks and 12 weeks postoperatively;
      health-related and vision-related quality of life at 12 weeks postoperatively; incremental
      cost-effectiveness ratios of the costs per quality-adjusted life year (QALY) and costs per
      improved patient on the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25)
      and Health Utility Index (HUI-3).

      In case of clinically significant macular edema, treatment will be initiated and its effect
      will be part of the evaluation at 12 weeks. Medical data of all patients who develop macular
      edema during this study will be checked at least 6 months after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change in central subfield mean macular thickness as a measurement of efficacy</measure>
    <time_frame>6 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the change in central subfield mean macular thickness in the 1 mm area (central subfield macular thickness, CSMT) as compared to baseline within the first 6 weeks postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No. of subjects developing clinically significant macular edema as a measurement of efficacy</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary endpoint is the occurrence of postoperative clinically significant macular edema (CSME) within 12 weeks postoperatively.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in corrected distance visual acuity (CDVA) as a measurement of efficacy</measure>
    <time_frame>6 postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>CDVA measurements will be taken using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts (logMAR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in retinal thickness in the central inner circle (3mm) as a measurement of efficacy</measure>
    <time_frame>6 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using Optical Coherence Tomography (OCT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraocular pressure (IOP) as a measurement of safety</measure>
    <time_frame>6 postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>IOP (in mmHg) will be measured by Goldmann applanation tonometry</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-related quality of life as a measurement of efficacy and tolerability</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using the Health Utility Index mark 3 (HUI-3)</description>
  </other_outcome>
  <other_outcome>
    <measure>No. of subjects with Adverse Events as a measurement of safety and tolerability</measure>
    <time_frame>6 weeks postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An adverse event (AE) is defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the investigational product. All adverse events reported spontaneously by the subject or observed by the principal investigator or his staff will be recorded.
Most frequently reported adverse events which might occur while using the study medication: abnormal sensation in the eye, pain or irritation, redness or headache while using eye drops; increased IOP and masking of infections while using corticosteroids; retinal detachment, thrombo-embolic events, endophthalmitis and anterior chamber reactions after intravitreal injections of bevacizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in retinal thickness in the central outer circle (6mm) as a measurement of efficacy</measure>
    <time_frame>6 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using OCT</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in macular volume as a measurement of efficacy</measure>
    <time_frame>6 postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using OCT</description>
  </other_outcome>
  <other_outcome>
    <measure>Vision-related quality of life as a measurement of efficacy and tolerability</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using the National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ 25)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incremental cost-effectiveness ratios of the costs per quality-adjusted life year (QALY) and costs per improved patient on the NEI VFQ-25 and HUI-3.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in corrected distance visual acuity (CDVA) as a measurement of efficacy</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>CDVA measurements will be taken using ETDRS visual acuity testing charts (logMAR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in retinal thickness in the central inner circle (3mm) as a measurement of efficacy</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using Optical Coherence Tomography (OCT)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraocular pressure (IOP) as a measurement of safety</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>IOP (in mmHg) will be measured by Goldmann applanation tonometry</description>
  </other_outcome>
  <other_outcome>
    <measure>No. of subjects with Adverse Events as a measurement of safety and tolerability</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An adverse event (AE) is defined as any undesirable experience occurring to a subject during the study, whether or not considered related to the investigational product. All adverse events reported spontaneously by the subject or observed by the principal investigator or his staff will be recorded.
Most frequently reported adverse events which might occur while using the study medication: abnormal sensation in the eye, pain or irritation, redness or headache while using eye drops; increased IOP and masking of infections while using corticosteroids; retinal detachment, thrombo-embolic events, endophthalmitis and anterior chamber reactions after intravitreal injections of bevacizumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in retinal thickness in the central outer circle (6mm) as a measurement of efficacy</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using OCT</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in macular volume as a measurement of efficacy</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using OCT</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in central subfield mean macular thickness as a measurement of efficacy</measure>
    <time_frame>12 weeks postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using OCT</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Cystoid Macular Edema</condition>
  <condition>Cataract</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Non diabetics: bromfenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non diabetics: dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non diabetics: bromfenac &amp; dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative &amp; dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics: eye drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative &amp; dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics: eye drops &amp; TA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative &amp; dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
&amp; a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics: eye drops &amp; bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative &amp; dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
&amp; a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetics: eye drops, TA &amp; bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
&amp; a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)
&amp; a peroperative intravitreal injection of 1.25 mg bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac</intervention_name>
    <description>n/a</description>
    <arm_group_label>Non diabetics: bromfenac</arm_group_label>
    <arm_group_label>Non diabetics: bromfenac &amp; dexamethasone</arm_group_label>
    <arm_group_label>Diabetics: eye drops</arm_group_label>
    <arm_group_label>Diabetics: eye drops &amp; TA</arm_group_label>
    <arm_group_label>Diabetics: eye drops &amp; bevacizumab</arm_group_label>
    <arm_group_label>Diabetics: eye drops, TA &amp; bevacizumab</arm_group_label>
    <other_name>Yellox</other_name>
    <other_name>Product code: EMEA/H/C/001198</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>n/a</description>
    <arm_group_label>Non diabetics: dexamethasone</arm_group_label>
    <arm_group_label>Non diabetics: bromfenac &amp; dexamethasone</arm_group_label>
    <arm_group_label>Diabetics: eye drops</arm_group_label>
    <arm_group_label>Diabetics: eye drops &amp; TA</arm_group_label>
    <arm_group_label>Diabetics: eye drops &amp; bevacizumab</arm_group_label>
    <arm_group_label>Diabetics: eye drops, TA &amp; bevacizumab</arm_group_label>
    <other_name>Dexamethasone ophthalmic solution</other_name>
    <other_name>Product code (NL): RVG 56003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>n/a</description>
    <arm_group_label>Diabetics: eye drops &amp; bevacizumab</arm_group_label>
    <arm_group_label>Diabetics: eye drops, TA &amp; bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Product code: EU/1/04/300/002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>n/a</description>
    <arm_group_label>Diabetics: eye drops &amp; TA</arm_group_label>
    <arm_group_label>Diabetics: eye drops, TA &amp; bevacizumab</arm_group_label>
    <other_name>Triesence or Vistrec</other_name>
    <other_name>Product code (NL): RVG 106092</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing routine phacoemulsification (one eye per patient)

          -  willing and/or able to comply with the scheduled visits and other study procedures.

          -  able to communicate properly and understand instructions.

          -  accepting possible off-label use of intravitreal bevacizumab and/or subconjunctival
             preservative-free TA.

        Exclusion criteria will be different for non-diabetic and diabetic patients. All
        ophthalmic exclusion criteria are applicable to the study eye only, unless stated
        otherwise.

        General exclusion criteria for participation in this study are:

          1. age below 21 years old;

          2. participation in another clinical study;

          3. post-traumatic cataract;

          4. combined surgery;

          5. functional monoculus;

          6. previous ocular surgery;

          7. progressive glaucoma with severe visual field defects, use of anti-glaucomatous
             medication or steroid-induced IOP elevation that required IOP-lowering treatment;

          8. IOP ≥ 25 mmHg;

          9. history of any intraocular inflammation or uveitis;

         10. history of pseudoexfoliation syndrome, which is expected to cause peroperative
             complications;

         11. history of Fuchs' endothelial dystrophy or cornea guttata 3+;

         12. history of retinal vein occlusion;

         13. any macular pathology that might influence VA, other than DME;

         14. use of intravitreal bevacizumab or ranibizumab in the previous 6 weeks or
             intravitreal aflibercept in the previous 10 weeks;

         15. use of intra- or periocular corticosteroid injection in the previous 4 months;

         16. current use of topical NSAIDs or corticosteroids;

         17. use of systemic corticosteroids (≥ 20 mg prednisolone or equivalence);

         18. history of relevant adverse events, including serious adverse events (SAE), occurring
             after administration of NSAIDs, acetylsalicylic acid, sodium sulphite,
             corticosteroids or bevacizumab;

         19. contraindications for use of topical NSAIDs, topical or subconjunctival
             corticosteroids or intravitreal bevacizumab or related drugs;

        Non-diabetic patients with a history of CME will be excluded from participation in the
        study.

        Additionally, diabetic patients will be excluded from participation in case of:

          1. macular edema with a CSMT ≥450 µm;

          2. very severe NPDR or proliferative DR requiring panretinal photocoagulation or
             vitrectomy;

          3. vitreous haemorrhage present during preoperative visit(s);

          4. cerebrovascular accident (CVA), myocardial infarction (MI) or other thromboembolic
             events in the previous 3 months;

          5. a history of recurrent thromboembolic events;

          6. a history of severe systemic bleeding in the previous 3 months;

          7. major surgery in the previous 3 months;

          8. history of glaucoma;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>prof. Rudy MM Nuijts, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Eye Clinic Maastricht, University Hospital Maastricht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>prof. Rudy MM Nuijts, MD, PhD</last_name>
    <phone>+31 43 387 7125</phone>
    <email>rudy.nuijts@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura HP Wielders, MD</last_name>
    <phone>+31 43 387 7131</phone>
    <email>laura.wielders@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery, Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>prof. O. Findl, MD, PhD</last_name>
      <phone>+43 67 6382 8538</phone>
      <email>oliver@findl.at</email>
    </contact>
    <investigator>
      <last_name>prof. O. Findl, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>prof. M. Tassignon, MD, PhD</last_name>
      <phone>+32 3 821 33 77</phone>
      <email>marie-jose.tassignon@uza.be</email>
    </contact>
    <investigator>
      <last_name>prof. M. Tassignon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenklinik Spreebogen</name>
      <address>
        <city>Berlin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>prof. M. Tetz, MD, PhD</last_name>
      <phone>+49 30 3980 98 0</phone>
      <email>manfred.tetz@atk-spreebogen.de</email>
    </contact>
    <investigator>
      <last_name>prof. M. Tetz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goethe University</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>prof. T. Kohnen, MD, PhD</last_name>
      <phone>+49 69 6301 3945</phone>
      <email>kohnen@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>prof. T. Kohnen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>H-1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>prof. Z. Nagy, MD, PhD</last_name>
      <phone>+36 20 825 8468</phone>
      <email>nagy.zoltan_zsolt@med.semmelweis-univ.hu</email>
    </contact>
    <investigator>
      <last_name>prof. Z. Nagy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital and University of Verona</name>
      <address>
        <city>Salo</city>
        <zip>25087</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>prof. R. Bellucci, MD, PhD</last_name>
      <phone>+39 347 657 5001</phone>
      <email>roberto.bellucci@ospedaleuniverona.it</email>
    </contact>
    <investigator>
      <last_name>prof. R. Bellucci, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. R Schlingemann, MD, PhD</last_name>
      <phone>+31 20 566 3682</phone>
      <email>r.schlingemann@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>prof. R. Schlingemann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regiopraktijk Heerlen, Atrium Medisch Centrum Parkstad</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>prof. Rudy MM Nuijts, MD, PhD</last_name>
      <phone>+31 43 3877344</phone>
      <email>rudy.nuijts@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>prof. Rudy MM Nuijts, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eye Hospital Zonnestraal</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>A. Rulo, MD, PhD</last_name>
      <phone>+31 35 772 5561</phone>
      <email>a.rulo@oogziekenhuiszonnestraal.nl</email>
    </contact>
    <investigator>
      <last_name>A Rulo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Rudy MM Nuijts, MD, PhD</last_name>
      <phone>+31 43 3877344</phone>
      <email>rudy.nuijts@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Laura HP Wielders, MD</last_name>
      <phone>+31 43 387 7131</phone>
      <email>laura.wielders@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Prof. Rudy MM Nuijts, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Centre Haaglanden</name>
      <address>
        <city>the Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Joosse, MD, PhD</last_name>
      <phone>+31 70 330 2937</phone>
      <email>m.joosse@mchaaglanden.nl</email>
    </contact>
    <investigator>
      <last_name>M Joosse, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>O Goslings, MD, PhD</last_name>
      <phone>+31 13 539 8020</phone>
      <email>o.goslings@elisabeth.nl</email>
    </contact>
    <investigator>
      <last_name>O Goslings, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>prof. J. Murta, MD, PhD</last_name>
      <phone>+ 351 239 701182</phone>
      <email>jmurta@huc.min-saude.pt</email>
    </contact>
    <investigator>
      <last_name>prof. J. Murta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Microcirurgia Ocular</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>prof. J. Guell, MD, PhD</last_name>
      <phone>+34 9325 31500</phone>
      <email>guell@imo.es</email>
    </contact>
    <investigator>
      <last_name>prof. J. Guell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
